Zhaotai Zongheng Biotechnology

Zhaotai Zongheng Biotechnology is a China-based, clinical-stage biotechnology company focused on the research and development of innovative chimeric antigen receptor T-cell (CAR-T) therapies, specifically targeting solid tumors. The company aims to overcome the traditional challenges of cell therapy in solid tumors, such as poor infiltration and the immunosuppressive microenvironment, through advanced engineering of T-cells. Their lead programs focus on high-prevalence indications in Asia, including hepatocellular carcinoma and pancreatic cancer, utilizing targets like Glypican 3 and Mesothelin. Zhaotai Zongheng operates primarily out of Changsha, leveraging proprietary platforms to enhance the persistence and safety profiles of their cell products. The company is part of a broader ecosystem of Chinese biotech firms advancing next-generation immunotherapy.